Trial Profile
Prediction of the efficacy of exenatide treatment in suboptimally controlled type 2 diabetic patients by Metabolic Fingerprint and evidence-based KADIS decision support: a clinical pilot trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2013
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms KADIS-Byetta
- 30 Nov 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 25 Apr 2012 New trial record